0000950170-23-065611.txt : 20231121 0000950170-23-065611.hdr.sgml : 20231121 20231121173004 ACCESSION NUMBER: 0000950170-23-065611 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231117 FILED AS OF DATE: 20231121 DATE AS OF CHANGE: 20231121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Jonathan CENTRAL INDEX KEY: 0001779805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 231429272 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2023-11-17 0001744659 Akero Therapeutics, Inc. AKRO 0001779805 Young Jonathan C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Operating Officer false Common Stock 2023-11-17 4 S false 30000 14.6753 D 153177 D Common Stock 20000 I By EA Irrevocable Trust Common Stock 20000 I By CM Irrevocable Trust Common Stock 20000 I By JL Irrevocable Trust The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.038, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request. These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. /s/ Jonathan Young 2023-11-21